Smith Nephew Aktie
11,68 EUR +0,02 EUR +0,13 %
STU
9,77 GBP -0,03 GBP -0,35 %
LSE
Werbung
Smith Nephew Rating
Smith & Nephew plc Aktie Moody's Rating
Baa2
C
A3
Aaa
Investmentwürdig - Hohe Sicherheit
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
| Rating | Baa2 | Rating Typ Bank Financial Strength Rating Insurance Financial Strength Rating Enhanced Rating Insured Rating Long-Term Bank Deposit Rating Long-Term OSO Rating Long-Term Debt Rating Money Market Fund Rating Modeled Shadow Rating Management Quality Rating Probability of Default Rating Pfd/Pref Stock Rating Prospective Pfd/Pref Rating Short-Term Bank Deposit Rating Speculative Grade Liquidity Rating Prospective LT Debt Rating Short-Term Insurance Financial Strength Rating Short-Term OSO Rating Servicer Quality Short-Term Debt Rating Lloyd´s Syndicate Performance Rating Underlying Rating Unknown - for conversion use only | Long-Term Debt Rating |
| Letzte Aktion | AFFIRM | Moody's Büro in | - |
Moody's Ratings Peer Group
| Aktie | Rating |
|---|---|
| Fresenius SE & Co. KGaA (St.) | Ba1 |
| Fresenius SE & Co. KGaA (St.) | Baa3 |
Beste Ratings aus der gleichen Branche
| Aktie | Rating |
|---|---|
| General Electric Co. | A1 |
| AstraZeneca PLC | A2 |
| DSM NV | A3 |
| 3M Co. | A3 |
| Siemens AG | Aa3 |
| Abbott Laboratories | Aa3 |
| Johnson & Johnson | Aaa |
| Fresenius SE & Co. KGaA (St.) | Ba1 |
| Akzo Nobel N.V. (Spons. ADRS) | Baa2 |
| Bayer | Baa3 |